Alexion Deal Adds Up For AstraZeneca's Rare Disease Specialist CFO
Marc Dunoyer Previously Led GSK's Orphan Operations
The proposed $39bn acquisition of Alexion by AstraZeneca has a particular interest for its chief financial officer Marc Dunoyer who recently spoke to Scrip about his extensive experience in the rare disease space.
